The objective of this study is to evaluate the safety and effectiveness of an investigational IOL in providing a range of vision as compared to a commercially available trifocal IOL in subjects undergoing cataract extraction and IOL implantation.

Upon obtaining written informed consent and confirmation of subject eligibility via preoperative assessments, subjects were randomized in a 1:1 ratio to receive either the investigational IOL or the commercially available trifocal IOL in both eyes. The second eye for each subject was implanted after completion of the 1-week follow up for the first implanted eye. The expected total duration of participation for each subject was up to 14 months.

Key Inclusion Criteria:

• Require cataract extraction by phacoemulsification;
• Corrected Distance Visual Acuity (CDVA) worse than 20/40 Snellen, or presence of visually significant lens opacity;
• Preoperative or predicted postoperative astigmatism of ≤ 1.0 diopter.

Key Exclusion Criteria:

• Use of current medications that may affect accommodation or confound study results;
• Systemic disease that may increase the operative risk or confound results;
• Ocular conditions or degenerative disorders that may predispose the subject to future complications;
• Monocular subjects or significant permanent visual function loss in 1 eye;
• Previous ocular surgery in either eye that may confound the results or increase the risk to the subject.